Biography

• Associate Investigator, College of Chemistry and Molecular Engineering, Peking University (2023-present)

•  Postdoctoral Fellow, Peking University (2021-2023)

• Ph.D., Peking University (2016-2021)

• B.S., Wuhan University (2012-2016)

Research Interests

Tumors represent inherently complex multicellular ecosystems, wherein malignant cells coexist and dynamically interact with diverse non-neoplastic cell populations, collectively determining the tumor progression. Our research focuses on advancing and leveraging bioorthogonal chemistry for tumor multicellular complexity, including (1) the development of bioorthogonal multimodal targeting chimeras as innovative tools or therapeutic modality to orchestrate multicellular interactions, and (2) tumor-targeted bioorthogonal prodrug therapy for precise elimination of tumor cells.

Selected Publications

1. Lin F, Yin S, Zhang Z, et al. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell. 2024, 187(26): 7470-7491.e32.

2. Zhang Y,^# Zhang Z,^# Lin F.* Multi-TACs: Targeting Solid Tumors with Multiple Immune Cell Co-engagers. ACS Chem Biol. 2025, 20(2): 245-247.

3. Lin F, Chen L, Zhang H, et al. Bioorthogonal Prodrug-Antibody Conjugates for On-Target and On-Demand Chemotherapy. CCS Chem. 2019, 1(2): 226-236.

4. Yao Q,^# Lin F,^# Lu C, et al. A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy. Bioconjugate Chem. 2023, 34(12), 2255-2262.

5. Chen P, Lin F, Lin J, Zhang H. Multi-specific bioconjugate linker and synthetic method therefor. Patent No: PCT/CN2021/130337, Granted: 2025-2-7.

6. Chen P, Zhang H, Han Y, Lin F, Lin J, Yang Y. Conjugate for target molecule modification and preparation method therefor. Patent No: PCT/CN2022/ 80594, Granted: 2023-3-31.